Polymedics Innovations

What Polymedics Innovations does

PolyMedics Innovations (PMI) is a privately held, family-run German medical device company founded in 2003-2004 and headquartered in Kirchheim unter Teck, Germany, with a US subsidiary in Woodstock, Georgia. The company develops, manufactures, and markets synthetic skin substitutes and wound healing products based on its proprietary Engineered Polylactide Technology platform (SUPRA EPT), a biodegradable polylactic acid polymer matrix that metabolizes fully to H₂O and CO₂ and creates a favorable wound healing environment through lactate-mediated mechanisms including pH modulation, VEGF upregulation, and reduced MMP activity. Its commercial product family consists of three core SKUs: SUPRATHEL, a synthetic epidermal substitute for partial-thickness burns, split-thickness skin graft donor sites, and conditions such as Stevens-Johnson Syndrome; SUPRA SDRM, a synthetic dermal regeneration matrix for complex and chronic wounds including diabetic foot ulcers and venous leg ulcers; and SUPRA NET, a net-like wound dressing variant. The company also distributes NexoBrid, an enzymatic debridement product, in Europe under a 2024 partnership with MediWound.

PMI sells to hospitals, burn centers, and wound care clinics through a hybrid go-to-market model: a wholly-owned US subsidiary handles North American direct sales, a network of regional distributors covers Latin America (Mexico, Panama, Peru, Ecuador, Argentina, Chile, Costa Rica, Dominican Republic) and parts of Europe, and the MediWound partnership extends reach in Europe. Products are regulatory-cleared in 40+ countries, including FDA and CE marking, with EU MDR compliance for its Class III devices. The company reports 250,000+ patients treated with SUPRATHEL over 20+ years of clinical use and claims market leadership in synthetic skin replacement materials, supported by an evidence base of multiple randomized controlled trials and 12 scientific publications in 2025 alone.

PMI is self-funded, self-sustaining, and has not raised institutional capital. It has stated organic growth of over 350% over the last five years. The business is owned and led by the Planck family, with Prof. Dr. Heinrich Planck and Christian Planck (CEO) serving as legal representatives. The company employs 11-50 people, runs R&D and manufacturing from Kirchheim unter Teck and Denkendorf, Germany, and is currently expanding clinical evidence in chronic wound indications while scaling its LATAM and US commercial footprint.

Name

Polymedics Innovations

Legal name

PolyMedics Innovations GmbH

Website

https://polymedics.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

PolyMedics Innovations is a German medical device company that develops and sells synthetic, biodegradable polylactide-based skin substitutes (SUPRATHEL, SUPRA SDRM, SUPRA NET) for hospitals, burn centers, and wound care clinics across 40+ countries, with a US subsidiary and European NexoBrid distribution partnership.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Synthetic skin substitutes
• Wound healing products
• Burn care devices
• Polylactide biomaterials
• Dermal regeneration matrix

Headquarters

HQ city

Denkendorf

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Medical Device Sales: PMI generates revenue through the sale of synthetic skin substitute products (SUPRATHEL, SUPRA SDRM, SUPRA NET) to healthcare providers including hospitals, burn centers, and clinics. Products are sold through direct sales (USA subsidiary), distributors (Latin America, Europe), and potentially OEM/channel partnerships.
2. International Distribution: Revenue generated through distribution partnerships in 40+ countries. The company is expanding global footprint annually through new market entries and regulatory approvals.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

PolyMedics Innovations (PMI) develops, manufactures, and markets synthetic skin substitutes and wound healing products based on its proprietary Engineered Polylactide Technology (SUPRA EPT). The company sells its core products SUPRATHEL, SUPRA SDRM, and SUPRA NET directly and through distributors to hospitals, burn centers, and wound care clinics in over 40 countries.

Product overview

PolyMedics Innovations (PMI) is a German medical device company specializing in synthetic skin substitutes and wound healing products based on proprietary Engineered Polylactide Technology (SUPRA EPT™). The product portfolio consists of three core synthetic wound care products: SUPRATHEL® (synthetic epidermal substitute for burns and donor sites), SUPRA SDRM® (synthetic dermal regeneration matrix for complex/chronic wounds), and SUPRA NET® (net-like wound dressing). The company also distributes NexoBrid® (enzymatic debridement agent) under a 2024 partnership with MediWound for European markets. All products are based on biodegradable polylactic acid polymers that create favorable wound healing environments through pH modulation and lactate-mediated mechanisms. PMI operates globally with distribution in over 40 countries and is family-owned with headquarters in Kirchheim unter Teck, Germany.

Differentiator

Problem solved

Functional benefit

Brands

• SUPRATHEL: Purely synthetic temporary skin substitute for burns, donor sites, and skin disorders. On the market for over 20 years, used in 40+ countries.
• SUPRA SDRM
• SUPRA NET
• SUPRA EPT

Products and services

• SUPRATHEL Synthetic skin substitute based on polylactide technology, used for treatment of partial-thickness burns, split-thickness skin graft (STSG) donor sites, and skin disorders like Stevens-Johnson Syndrome. The biodegradable matrix metabolizes to H2O and CO2 and has been on the market for over 20 years.
• SUPRA SDRM Synthetic dermal regeneration matrix (CAMP - Cellular, Acellular, and Matrix-like Product) based on polylactic acid for treatment of complex wounds including diabetic foot ulcers and venous leg ulcers. The porous foam matrix supports granulation and re-epithelialization.
• SUPRA NET
• NexoBrid (distribution) Enzymatic debridement product for burn treatment, distributed by PolyMedics Innovations in Europe under a November 2024 partnership agreement with MediWound.

Quantifiable outcome

• 50% faster healing for diabetic foot ulcers compared to collagen dressings and 20% faster than fish skin grafts
• +6 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• MediWound Ltd.coreChannel Partner/ Reseller/ Distributor · 1 November 2024PMI partnered with MediWound in November 2024 to expand distribution of Nexobrid across Europe. This partnership leverages PMI's established European distribution network and expertise in burn care to broaden patient access to Nexobrid treatment. MediWound received FDA approval for Nexobrid in August 2024 for pediatric patients with severe burns.
• Grupo Vuelo (Mexico)coreChannel Partner/ Reseller/ DistributorGrupo Vuelo serves as PMI's local distributor in Mexico, providing presence at the Mexican Burn Association conference and supporting clinical education and product adoption in the Mexican market.
• LATAM Distributors NetworkcoreChannel Partner/ Reseller/ DistributorPMI has established distributor relationships across Latin America including representatives in Panama, Peru, Ecuador, Argentina, Chile, Costa Rica, and Dominican Republic. Head of LATAM Commercial Operations (Beatriz Vega) manages these relationships and ensures product materials, studies, and resources are accessible to distributors.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Organogenesis Holdings: Pure-play regenerative medicine company selling bioengineered skin substitutes (e.g., Apligraf, Dermagraft) for chronic wounds and burns. Comparable because it competes head-to-head with SUPRATHEL and SUPRA SDRM in DFU/VLU and burn care, with overlapping clinical evidence and reimbursement strategies.
• MediWound: Specialty biopharmaceutical company focused on enzymatic burn debridement (NexoBrid), and PMI's distribution partner in Europe. Comparable because it addresses the same burn-care workflow, shares commercial relationships with burn centers, and provides strategic context for PMI's burn franchise.
• MiMedx Group: US-listed regenerative medicine company commercializing amniotic membrane-based wound-care and surgical recovery products (e.g., EpiFix). Comparable because it directly contests PMI in the chronic-wound and surgical-wound segments using biologic matrices.
• Kerecis (Coloplast): Fish-skin graft company acquired by Coloplast, focused on DFUs, VLUs, and burn wounds. Comparable because PMI's own clinical materials benchmark SUPRA SDRM directly against Kerecis products, confirming direct competition in chronic-wound and burn indications.

Broad incumbents

• Coloplast: Global wound and ostomy care leader that owns Kerecis. Comparable as a broader incumbent with growing presence in advanced wound care and skin substitutes, directly relevant for assessing PMI's competitive positioning in DFU/VLU.
• Solventum (3M Health Care spin-off): Large diversified health-care company with a significant advanced wound-care portfolio (formerly 3M Health Care). Comparable because it competes across dressings, negative-pressure wound therapy, and skin substitutes sold to the same HCP customers PMI serves.
• ConvaTec: Public wound-care specialist with a portfolio spanning advanced dressings, skin barriers, and regenerative technologies. Comparable because it competes directly in chronic-wound management (DFUs/VLUs) and burns — the same primary indications PMI addresses.
• Integra LifeSciences: Diversified medical device company with a dedicated regenerative tissue technologies business (Integra Dermal Regeneration Template). Comparable because it sells skin substitutes and wound matrices into burn and reconstructive surgery channels that overlap with PMI's call point.
• Smith+Nephew: Global medical devices major with a sizable Advanced Wound Management portfolio (including skin substitutes and dermal matrices). Comparable because it sells wound-care products into the same hospitals, burn centers, and outpatient clinics that PMI targets, though it operates across many other orthopedics/sports medicine categories as well.
• Mölnlycke Health Care: Large wound-care and surgical solutions provider with Mepilex and other advanced wound dressings. Comparable because it serves identical burn and chronic-wound HCP customers and competes for the same hospital formulary slots as PMI's synthetic skin substitutes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCW30aWgD0Xi_7WekUfk7zLw
• LinkedInlinkedin.com/company/polymedics-innovations

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polymedics Innovations